These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23734673)

  • 41. Octahydropyrrolo[3,4-c]pyrrole: a diamine scaffold for construction of either alpha4beta2 or alpha7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity.
    Bunnelle WH; Tietje KR; Frost JM; Peters D; Ji J; Li T; Scanio MJ; Shi L; Anderson DJ; Dyhring T; Grønlien JH; Ween H; Thorin-Hagene K; Meyer MD
    J Med Chem; 2009 Jul; 52(14):4126-41. PubMed ID: 19552432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and pharmacological evaluation of some (pyridyl)cyclopropylmethyl amines and their methiodides as nicotinic receptor ligands.
    Guandalini L; Dei S; Manetti D; Romanelli MN; Scapecchi S; Teodori E; Varani K
    Farmaco; 2002 Jun; 57(6):487-96. PubMed ID: 12088064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them.
    Xiao Y; Fan H; Musachio JL; Wei ZL; Chellappan SK; Kozikowski AP; Kellar KJ
    Mol Pharmacol; 2006 Oct; 70(4):1454-60. PubMed ID: 16857741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemistry and Pharmacology of a Series of Unichiral Analogues of 2-(2-Pyrrolidinyl)-1,4-benzodioxane, Prolinol Phenyl Ether, and Prolinol 3-Pyridyl Ether Designed as α4β2-Nicotinic Acetylcholine Receptor Agonists.
    Bolchi C; Valoti E; Gotti C; Fasoli F; Ruggeri P; Fumagalli L; Binda M; Mucchietto V; Sciaccaluga M; Budriesi R; Fucile S; Pallavicini M
    J Med Chem; 2015 Aug; 58(16):6665-77. PubMed ID: 26225816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and nicotinic binding studies on enantiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo[4.2.1]non-2-ene UB-165.
    Gohlke H; Gündisch D; Schwarz S; Seitz G; Tilotta MC; Wegge T
    J Med Chem; 2002 Feb; 45(5):1064-72. PubMed ID: 11855986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic doses of antidepressants are projected not to inhibit human α4β2 nicotinic acetylcholine receptors.
    Weber ML; Hofland CM; Shaffer CL; Flik G; Cremers T; Hurst RS; Rollema H
    Neuropharmacology; 2013 Sep; 72():88-95. PubMed ID: 23639435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain.
    Meyer MD; Decker MW; Rueter LE; Anderson DJ; Dart MJ; Kim KH; Sullivan JP; Williams M
    Eur J Pharmacol; 2000 Mar; 393(1-3):171-7. PubMed ID: 10771011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.
    Carroll FI; Navarro HA; Mascarella SW; Castro AH; Luetje CW; Wageman CR; Marks MJ; Jackson A; Damaj MI
    ACS Chem Neurosci; 2015 Jun; 6(6):920-6. PubMed ID: 25891987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential nicotinic acetylcholine receptor ligands from 2,4-methanoproline derivatives.
    Patel AB; Malpass JR
    J Med Chem; 2008 Nov; 51(21):7005-9. PubMed ID: 18841955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic oral nicotine increases brain [3H]epibatidine binding and responsiveness to antidepressant drugs, but not nicotine, in the mouse forced swim test.
    Andreasen JT; Nielsen EO; Redrobe JP
    Psychopharmacology (Berl); 2009 Aug; 205(3):517-28. PubMed ID: 19452140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain.
    Nirogi R; Goura V; Abraham R; Jayarajan P
    Eur J Pharmacol; 2013 Jul; 712(1-3):22-9. PubMed ID: 23660369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of novel alpha7-subtype-preferring nicotinic acetylcholine receptor agonists: application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies.
    Grazioso G; Pomè DY; Matera C; Frigerio F; Pucci L; Gotti C; Dallanoce C; De Amici M
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6353-7. PubMed ID: 19804970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
    Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
    J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of the nicotinic receptor β4 subunit in the antidepressant activity of novel N,6-dimethyltricyclo[5.2.1.0²,⁶]decan-2-amine enantiomers.
    Targowska-Duda KM; Jozwiak K; Arias HR
    Neurosci Lett; 2013 Oct; 553():186-90. PubMed ID: 23994392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
    Holladay MW; Wasicak JT; Lin NH; He Y; Ryther KB; Bannon AW; Buckley MJ; Kim DJ; Decker MW; Anderson DJ; Campbell JE; Kuntzweiler TA; Donnelly-Roberts DL; Piattoni-Kaplan M; Briggs CA; Williams M; Arneric SP
    J Med Chem; 1998 Feb; 41(4):407-12. PubMed ID: 9484491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-substituted deschloroepibatidine analogues. Novel nicotinic antagonists.
    Carroll FI; Ma W; Yokota Y; Lee JR; Brieaddy LE; Navarro HA; Damaj MI; Martin BR
    J Med Chem; 2005 Feb; 48(4):1221-8. PubMed ID: 15715488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.
    Abreo MA; Lin NH; Garvey DS; Gunn DE; Hettinger AM; Wasicak JT; Pavlik PA; Martin YC; Donnelly-roberts DL; Anderson DJ; Sullivan JP; Williams M; Arneric SP; Holladay MW
    J Med Chem; 1996 Feb; 39(4):817-25. PubMed ID: 8632405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).
    Zanaletti R; Bettinetti L; Castaldo C; Cocconcelli G; Comery T; Dunlop J; Gaviraghi G; Ghiron C; Haydar SN; Jow F; Maccari L; Micco I; Nencini A; Scali C; Turlizzi E; Valacchi M
    J Med Chem; 2012 May; 55(10):4806-23. PubMed ID: 22468936
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.
    Onajole OK; Eaton JB; Lukas RJ; Brunner D; Thiede L; Caldarone BJ; Kozikowski AP
    ACS Med Chem Lett; 2014 Nov; 5(11):1196-201. PubMed ID: 25408831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95.
    Kong H; Song JK; Yenugonda VM; Zhang L; Shuo T; Cheema AK; Kong Y; Du GH; Brown ML
    Mol Pharm; 2015 Feb; 12(2):393-402. PubMed ID: 25533629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.